These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 21717064)

  • 1. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity.
    Lee SC; Srivastava RM; López-Albaitero A; Ferrone S; Ferris RL
    Immunol Res; 2011 Aug; 50(2-3):248-54. PubMed ID: 21717064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
    Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL
    Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
    Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
    Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
    Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
    Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells.
    Deauvieau F; Ollion V; Doffin AC; Achard C; Fonteneau JF; Verronese E; Durand I; Ghittoni R; Marvel J; Dezutter-Dambuyant C; Walzer T; Vie H; Perrot I; Goutagny N; Caux C; Valladeau-Guilemond J
    Int J Cancer; 2015 Mar; 136(5):1085-94. PubMed ID: 25046660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.
    Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL
    Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
    Boyerinas B; Jochems C; Fantini M; Heery CR; Gulley JL; Tsang KY; Schlom J
    Cancer Immunol Res; 2015 Oct; 3(10):1148-1157. PubMed ID: 26014098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk--a pivotal role of HMGB1.
    Melki MT; Saïdi H; Dufour A; Olivo-Marin JC; Gougeon ML
    PLoS Pathog; 2010 Apr; 6(4):e1000862. PubMed ID: 20419158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
    Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
    BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
    Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
    Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.
    Battella S; Cox MC; Santoni A; Palmieri G
    J Leukoc Biol; 2016 Jan; 99(1):87-96. PubMed ID: 26136506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
    Cooley S; Burns LJ; Repka T; Miller JS
    Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
    Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
    Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cells, particularly activated CD4
    Wang Z; Chimenti MS; Strouse C; Weiner GJ
    Cancer Immunol Immunother; 2022 Feb; 71(2):237-249. PubMed ID: 34110453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired dendritic cell functions because of depletion of natural killer cells disrupt antigen-specific immune responses in mice: restoration of adaptive immunity in natural killer-depleted mice by antigen-pulsed dendritic cell.
    Yoshida O; Akbar F; Miyake T; Abe M; Matsuura B; Hiasa Y; Onji M
    Clin Exp Immunol; 2008 Apr; 152(1):174-81. PubMed ID: 18307521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
    Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
    Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.
    Lu S; Zhang J; Liu D; Li G; Staveley-O'Carroll KF; Li Z; Wu JD
    Clin Cancer Res; 2015 Nov; 21(21):4819-30. PubMed ID: 26106076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.
    Groh V; Li YQ; Cioca D; Hunder NN; Wang W; Riddell SR; Yee C; Spies T
    Proc Natl Acad Sci U S A; 2005 May; 102(18):6461-6. PubMed ID: 15824323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells.
    Yu Y; Hagihara M; Ando K; Gansuvd B; Matsuzawa H; Tsuchiya T; Ueda Y; Inoue H; Hotta T; Kato S
    J Immunol; 2001 Feb; 166(3):1590-600. PubMed ID: 11160200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.